Intrathecally injected Ile-Pro-Ile, an inhibitor of membrane ectoenzyme dipeptidyl peptidase IV, is antihyperalgesic in rats by switching the enzyme from hydrolase to synthase functional mode to generate endomorphin 2

European Journal of Pharmacology

Volumn 620, Issue 1-3, 2009, Pages 21-26

  Király, Kornél ^a   Szalay, Balázs ^a   Szalai, Judit ^a   Barna, István ^b   Gyires, Klára ^a   Verbeken, Mathieu ^c   Rónai, András Z ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Carrageenan hyperalgesia; Dipeptidyl peptidase IV; Endomorphin 2 biosynthesis; Ile Pro Ile; Intrathecal administration

Indexed keywords

CARRAGEENAN; DIPROTIN A; ENDOMORPHIN 1; ENDOMORPHIN 2; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; HYDROLASE; MORPHINE; NALOXONE; OPIATE RECEPTOR; SYNTHETASE;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HYPERALGESIA; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; SPINAL CORD DORSAL HORN; TAIL FLICK TEST;

ANIMALS; ANTIGENS, CD26; CARRAGEENAN; CELL MEMBRANE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HYPERALGESIA; INJECTIONS, SPINAL; LIGASES; MALE; OLIGOPEPTIDES; RATS; RATS, WISTAR;

EID: 70349133917     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.08.018     Document Type: Article

References (41)

1. Al-Khrasani M., Orosz G., Kocsis L., Farkas V., Magyar A., Lengyel I., Benyhe S., Borsodi A., and Rónai A.Z. Receptor constants for endomorphin-1 and endomorphin-1-ol indicate differences in efficacy and receptor occupancy. Eur. J. Pharmacol. 421 (2001) 61-67
2. 35 S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor. J. Pharmacol. Exp. Ther. 286 (1998) 282-288
3. Clapés P., Torres J.L., and Adlercreutz P. Enzymatic peptide synthesis in low water content systems: preparative enzymatic synthesis of [Leu]- and [Met]-enkephalin derivatives. Bioorg. Med. Chem. 3 (1995) 245-255
4. Czapla M.A., Gozal D., Alea O.A., Beckerman R.C., and Zadina J.E. Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO and morphine. Am. J. Respir. Crit. Care Med. 162 (2000) 994-999
5. D'Amour F.E., and Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72 (1941) 74-79
6. Eipper B.A., and Mains R.E. Peptide α-amidation. Annu. Rev. Physiol. 50 (1988) 333-344
7. Eipper B.A., Mains R.E., and Glembotski C.C. Identification in pituitary tissue of a peptide α -amidation activity that acts on glycine-extended peptides and requires molecular oxygen, copper, and ascorbic acid. Proc. Natl. Acad. Sci. USA 80 (1983) 51144-51148
8. Fichna J., Janecka A., Costentin J., and Do Rego J.-C. The endomorphin system and its evolving neurophysiological role. Pharmacol. Rev. 59 (2007) 88-123
9. Gibson J., Polak J.M., Allen J.M., Adrian T.E., Kelly J.S., and Bloom S.R. The distribution and origin of a novel brain peptide, neuropeptide Y, in the spinal cord of several mammals. J. Comp. Neurol. 227 (1984) 78-91
10. Gorrell M.D., Gysbers V., and McCaughan G.W. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand. J. Immunol. 54 (2001) 249-264
11. Horvath G. Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous μ-opioid receptor agonists. Pharmacol. Ther. 88 (2000) 437-463
12. Hosohata K., Burkey T.H., Alfaro-Lopez J., Varga E., Hruby V.J., Roeske W.R., and Yamamura H.I. Endomorphin-1 and endomorphin-2 are partial agonists at the human μ-opioid receptor. Eur. J. Pharmacol. 346 (1998) 111-1148
13. Lai J., Luo M.-C., Chen Q., Ma S., Gardell L.R., Ossipov M.H., and Porreca F. Dynorphin A activates bradykinin receptors to maintain neuropathic pain. Nature Neurosci. 9 (2006) 1534-1540
14. Lisi T.L., and Sluka K.A. A new electrochemical HPLC method for analysis of enkephalins and endomorphins. J. Neurosci. Methods 150 (2006) 74-79
15. Martin-Schild S., Zadina J.E., Gerall A.A., Vigh S., and Kastin A.J. Localization of endomorphin-2-like immunoreactivity in the rat medulla and spinal cord. Peptides 18 (1997) 1641-1649
16. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Reg. Pept. 85 (1999) 9-24
17. Mestre C., Pélissier T., Fialip J., Wilcox G., and Eschalier A. A method to perform direct transcutaneous intrathecal injection in rats. J. Pharmacol. Toxicol. Meth. 32 (1994) 197-200
18. Moore K.B., and Saudek C.D. Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus. Am. J. Ther. 15 (2008) 484-491
19. Neubig R.R., Spedding M., Kenakin T., and Christopoulos A. International Union of Pharmacology Commitee on receptor nomenclature and drug classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol. Rev. 55 (2003) 597-606
20. Pierce T.L., and Wessendorf M.W. Immunocytochemical mapping of endomorphin-2 immunoreactivity in rat brain. J. Chem. Neuroanat. 18 (2000) 181-207
21. Przewlocki R., and Przewlocka B. Opioids in chronic pain. Eur. J. Pharmacol. 429 (2001) 79-91
22. Randall L.O., and Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. 4 (1957) 409-419
23. Rónai A.Z., Timár J., Makó É., Erdõ F., Gyarmati Z., Tóth G., Orosz G., Fürst S., and Székely J.I. Diprotin A, an inhibitor of dipeptidyl aminopeptidase IV (EC 3.4.14.5) produces naloxone-reversible analgesia in rats. Life Sci. 64 (1998/99) 145-152
24. 3H]- Tyr-Pro: A possible biosynthetic route for endomorphins. Reg. Pept. 134 (2006) 54-60
25. Rónai A.Z., Király K., Szebeni A., Szemenyei E., Prohászka Z., Darula Zs., Tóth J.S., Till I., Szalay B., Kató E., and Barna I. Immunoreactive endomorphin 2 is generated extracellularly in rat isolated L4,5 dorsal root ganglia by DPP-IV. Reg. Pept. 157 (2009) 1-2
26. Rosenblum J.S., and Kozarich J.W. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Current Opinion Chem. Biol. 7 (2003) 496-504
27. Sanderson Nydahl K., Skinner K., Julius D., and Basbaum A.I. Co-localization of endomorphin-2 and substance P in primary afferent nociceptors and effects of injury: a light and electron microscopic study in the rat. Eur. J. Neurosci. 19 (2004) 1789-1799
28. Scanlin H.L., Carroll E.A., Jenkins V.K., and Balkowiec A. Endomorphin-2 is released from newborn rat primary sensory neuron sin a frequency- and calcium-dependent manner. Eur. J. Neurosci. 27 (2008) 2629-2642
29. Schuster M., Aaviksaar A., Haga M., Ullmann U., and Jakubke H.D. Protease-catalyzed peptide synthesis in frozen aqueous systems: the "freeze-concentration model". Biomed. Biochim. Acta 50 (1991) S84-S89
30. Skidgel R.A., Defendini R., and Erdös E.G. Angiotensin I converting enzyme and its role in neuropeptide metabolism. In: Turner A.J. (Ed). Neuropeptides and their peptidases (1987), Ellis Horwood Ltd, Chichester, England 165-182
31. Szemenyei E., Barna I., Mergl Z., Keresztes A., Darula Z., Kató E., Tóth G., and Rónai A.Z. Detection of a novel immunoreactive endomorphin 2-like peptide in rat brain extracts. Reg. Pept. 148 (2008) 54-61
32. Tanaka S., Murakami T., Horikawa H., Sugiura M., Kawashima K., and Sugita T. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int. J. Immunopharmacol. 19 (1997) 15-24
33. Terskiy A., Wannemacher K.M., Yadav P.N., Tsai M., Tian B., and Howells R.D. Search of the human proteome for endomorphin-1 and endomorphin-2 precursor proteins. Life Sci. 81 (2007) 1593-1601
34. Tömböly C., Péter A., and Tóth G. In vitro quantitative study of the degradation of endomorphins. Peptides 23 (2002) 1573-1580
35. Turner A.J. Endopeptidase-24.11 and neuropeptide metabolism. In: Turner A.J. (Ed) (1987), Ellis Horwood Ltd, Chichester, England 183-201
36. Umezawa H., Aoyagi T., Ogawa K., Naganawa H., Hamada M., and Takeuchi T. Diprotins A and B, inhibitors of dipeptidyl aminopeptidase IV, produced by bacteria. J Antibiot (Tokyo) 37 (1984) 422-425
37. Wang Q.P., Zadina J.E., Guan J.-L., Kastin A.J., Funahashi H., and Shoda S. Endomorphin-2 immunoreactivity in the cervical dorsal horn of the rat spinal cord at the electron microscopic level. Neurosci 113 (2002) 593-605
38. Wilson A.M., Soignier R.D., Zadina J.E., Kastin A.J., Nores W.L., Olson R.D., and Olson G.A. Dissociation of analgesic and rewarding effects of endomorphin-1 in rats. Peptides 21 (2000) 1871-1874
39. Wolfe D., Hao S., Hu J., Srinivasan R., Goss J., Mata M., Fink D.J., and Glorioso J.C. Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain 133 (2007) 29-38
40. Yaksh T.L. Spinal systems and pain processing: development of novel analgesic drugs with mechanistically defined models. Trends in Pharmacol. Sci. 20 (1999) 329-337
41. Zadina J.E., Hackler L., Ge L.-J., and Kastin A.J. A potent and selective endogenous agonist for the μ-opiate receptor. Nature 386 (1997) 499-502